SEC Filing Summary: Revelation Biosciences, Inc. (REVB)
Business Context and Reporting Period
This Form 8-K, dated November 6, 2025, serves as a current report for Revelation Biosciences, Inc., a Delaware corporation headquartered in San Diego, California. The filing references a press release issued on February 26, 2026, which announced financial results for the three and twelve months ended December 31, 2025. The company's common stock and redeemable warrants trade on The Nasdaq Stock Market LLC under the symbols REVB and REVBW, respectively.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced in a separate press release (Exhibit 99.1) but does not contain the financial data itself within the body of this 8-K.
Material Changes
No material changes versus prior periods are detailed in this filing text. The document solely references the issuance of the February 26, 2026, press release containing the comparative financial results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated. No specific guidance, management commentary, risks, or contingencies are described in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the press release dated February 26, 2026, referenced as Exhibit 99.1.
- Confirm the status of the redeemable warrants (REVBW) and their exercise price of $2,318,400 per share as listed in the securities registration section.
- Check for any subsequent filings that may incorporate the results from the February 26, 2026, press release by reference.
- Review the full text of the press release for any forward-looking statements or updated operational milestones not captured in this summary.